Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
In this medfyle
5-year survival data support the continued use of durvalumab consolidation after chemoradiotherapy as the standard of care in stage III NSCLC.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Expert commentary
About this Medfyle
This Medfyle is provided as a service to healthcare professionals. It has been created from content originally published in the Journal of Clinical Oncology® (JCO), an American Society of Clinical Oncology Journal, through an official agreement with Wolters Kluwer.
The summary content was prepared by Louise Gardner for Medfyle, reviewed & approved by Megan E. Daly, MD.
Original article:
David R. Spigel, Corinne Faivre-Finn, Jhanelle E. Gray, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. J Clin Oncol. 2022 Feb 2; JCO2101308. doi: 10.1200/JCO.21.01308. Online ahead of print.
The authors of the original article had no part in the creation of the summary.
All Medfyle content, summaries, expert commentaries and slides are owned by GlobalPort (International) Limited. The original journal articles are an exclusive copyright of the American Society of Clinical Oncology.
